167. マルファン症候群 Marfan syndrome Clinical trials / Disease details


臨床試験数 : 21 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01949233
(ClinicalTrials.gov)
October 20136/8/2013The Oxford Marfan TrialA Randomised, Double-blind, Placebo-controlled Pilot Trial of Irbesartan, Doxycycline and a Combination on Markers of Vascular Dysfunction in the Marfan Syndrome, Using Cardiovascular Magnetic Resonance ImagingMarfan SyndromeDrug: Irbesartan 150-300mg capsules daily for 6 months;Drug: Doxycycline 100-200mg capsules daily for 6 months;Drug: Doxycycline placebo capsules daily for 6 months;Drug: Irbesartan placebo capsules daily for 6 monthsUniversity of OxfordOxford University Hospitals NHS TrustRecruiting13 YearsN/ABoth56Phase 2United Kingdom
2EUCTR2010-023612-14-GB
(EUCTR)
08/03/201320/12/2012The Oxford Marfan Trial A randomised, double-blind, placebo-controlled pilot trial of irbesartan, doxycycline and a combination on markers of vascular dysfunction in the Marfan syndrome, using cardiovascular magnetic resonance imaging - The Oxford Marfan Trial Version 1.0 Marfan syndrome.
MedDRA version: 14.1;Level: PT;Classification code 10026829;Term: Marfan's syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Aprovel
Product Name: Aprovel
INN or Proposed INN: Irbesartan
Trade Name: Vibrox 100mg Capsules
Product Name: Vibrox
INN or Proposed INN: Doxycycline Hyclate Ph.Eur
Clinical Trials and Research GovernanceNULLNot Recruiting Female: yes
Male: yes
56 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom